The rate of positive E20 mutations in the whole blood sample (4.55%) was significantly higher than the other two sample types; however, there were no positive PIK3CA gene mutations detected in exon E20 among patients with different pathologic types or lung cancer stages (Table 10). This evidence concerns the gene PIK3CA and lung carcinoma.